「environment studies」に関連した英語例文の一覧と使い方 - Weblio英語例文検索

In connection with that view, we held another opinion that, although there exists precedent studies outside Japan, it is virtually difficult to apply such studies directly to Japan at this moment, because the Japanese market environment such as the corporate bond markets has not been improved appropriately. 例文帳に追加

これについては、海外においては先行研究が存在するものの、現時点において我が国に直接適用しモデル化することは、社債市場等マーケット環境が整備されていないことから事実上困難であるとの意見もあった。 - 財務省

To provide an environment for enabling a person, who studies singing, to receive the singing instruction of an expert by accessing the Internet from a personal computer at home, for example, while effectively utilizing an information technology related to the personal computer or the Internet.例文帳に追加

パソコンやインターネット関連の情報技術を活用し、歌の勉強をしている人がたとえば自宅のパソコンからインターネットにアクセスして専門家の歌唱指導を受けることができるような環境を創出する。 - 特許庁

With regard to expenditures for education and science, we are promoting measures to establish an environment for educational reforms, including the improvement of higher education and academic studies, and the promotion of science and technology, by increasing competitive funding, with the aim of establishing a creative and vital nation.例文帳に追加

文教及び科学振興費については、創造力と活力に富んだ国家を目指して、確かな学力の育成等教育改革の推進のための環境整備、高等教育・学術研究の充実、競争的資金の拡充等による科学技術の振興等に努めております。 - 財務省

As for expenditures on education and science, we are promoting measures, such as those aimed at the establishment of an environment for educational reform such as the implementation small-class education, etc., the improvement of higher education and academic studies, and the promotion of science and technology by increasing competitive funding, with the aim of establishing a creative and vital nation.例文帳に追加

文教及び科学振興費については、創造的で活力に富んだ国家を目指して、少人数指導の実施等教育改革の推進のための環境整備、高等教育・学術研究の充実、競争的資金の拡充等による科学技術の振興等の施策の推進に努めております。 - 財務省

Furthermore, as the presence of specialists who support the implementation is also important in clinical studies and trials, it is necessary to educate specialists such as clinical study coordinators and biostatisticians who support clinical studies. In addition, it is important to improve the medical environment where various pharmaceutical products developed can be properly used, and in consideration that pharmacotherapy, explanation to patients and instruction on dosage and administration in addition to the improvement of medical facilities can be adequately conducted, human resources development is also necessary for healthcare professionals such as physicians and pharmacists.例文帳に追加

さらに、臨床研究・治験においては、その実施をサポートする専門家の存在も重要であり、臨床研究コーディネーター、生物統計家等、臨床研究を支援する専門家の育成を図る必要がある。なお、種々の開発される医薬品等が適切に使用される医療環境の整備も重要であり、医療施設の整備の他、薬物療法や患者への説明、服薬指導等を適切に行うことができるようにするためという観点からの、医師、薬剤師等の医療関係者の人材育成も必要である。 - 厚生労働省

Private companies are also making efforts by offering training programs available during childcare leave to help them improve their skills while away from the job, providing nursery facilities within the company, teleworking, and re-employment systems for those who have left. Advancements in developing an environment in which women can actively participate in the workplace are expected as a result of case studies of advanced companies and publicizing best practices.例文帳に追加

民間企業においても、育児休暇を利用して研修を行い、スキル・アップを図る育児休暇中研修、事業所内保育施設、テレワーク、離職者の再雇用制度などの取組が進められており、先進的な企業の事例分析やベストプラクティスの公表を行うことによって、女性が活躍できる環境整備が促進されることが期待される。 - 経済産業省

In the mid-term review, the items that were being worked upon up to now for the infrastructure development of clinical trials and studies centered on core hospitals and central medical institutions, etc., were evaluated in view of the changes in the clinical trial/study environment, such as the rapid increase in the number of multinational clinical trials after the establishment of the 5 Yearly Plan, and the following items were set as the points for consideration:例文帳に追加

中間見直しにおいては、５カ年計画の策定後、急激に国際共同治験の実施数が増加している等の治験・臨床研究の環境の変化に鑑み、これまでに中核病院・拠点医療機関等を中心として治験・臨床研究の基盤整備に取り組んできた事項を評価するとともに、次の点を検討事項とした。 - 厚生労働省

However, even if the measured value was lower than the targeted value but exceeded the acceptable exposure concentration limit of 3×10－４mg/m3 that is a limit value calculated from the outcome of the test in long-term carcinogenicity studies in animals in this country, it is recommendable to take further actions as required continually to improve work environment and reduce the concentration of indium in air as much as possible.例文帳に追加

なお、目標濃度以下となった作業場についても、我が国における動物を用いた長期がん原性試験結果により算定したばく露が許容される濃度3×10－４mg/m3を超える場合にあっては、作業環境を改善するため必要な措置を継続的に講じ、できる限り空気中のインジウムの濃度を低減させることが望ましい。 - 厚生労働省

In order to assist the development of R&D strategy and IP strategy, the results of patent application technical trends surveys and other studies on selected technological themes will be made public available via the Patent Office’s website and other channels. These themes will focus mainly on “Green Innovation” (environment/energy) and “Life Innovation” (medical and health care) related technologies, which have been identified as being pivotal to Japan’s future growth and social development. (Continuation) (See p. 218.) 例文帳に追加

研究開発戦略や知的財産戦略構築を支援するために、日本の将来にわたる成長と社会の発展のための主要な柱として定められた「グリーン・イノベーション」（環境・エネルギー）、「ライフ・イノベーション」（医療・健康）関連分野を中心に選定した技術テーマについて、特許出願動向等の調査結果を、特許庁ホームページ等を通じて情報発信を行う。（継続）（p.226参照） - 経済産業省

In order to develop and reinforce a firm and internationally competitive infrastructure required for the implementation of clinical trials and clinical studies that lead to the creation of innovative pharmaceuticals and medical devices in Japan, it is necessary to steadily advance infrastructure development indicated in the "Functions Required of Core Hospitals and Central Medical Institutions" in core hospitals and central medical institutions, and this should be used as reference to improve the clinical trial and clinical research environment throughout Japan in other medical institutions as well.例文帳に追加

今後、我が国発の革新的な医薬品・医療機器の創出につながる治験・臨床研究実施に必要な確固たる、また国際競争力のある基盤を整備・強化するため、中核病院・ 拠点医療機関においては「中核病院・拠点医療機関へ求める機能」に示された基盤整備を着実に進めるとともに、他の医療機関においてもこれを参考に我が国全体の治験・ 臨床研究環境の改善に向けて取り組むべきである。 - 厚生労働省

Article 31-2 (1) A person engaged in the business of manufacturing or importing any chemical substance subject to monitoring, any Class II Specified Chemical Substance, any chemical substance of which the public has been notified pursuant to the provisions of Article 4, paragraph (4) (including where it is applied mutatis mutandis pursuant to Article 4-2, paragraph (9) and pursuant to Article 5-2, paragraph (2)), or any chemical substance in the list of existing chemical substances prescribed in Article 2, paragraph (1) of the Supplementary Provisions of which the public has been notified by the Minister of International Trade and Industry pursuant to the provisions of paragraph (4) of said Article (hereinafter referred to as a "substance subject to reporting") shall report to the Minister of Health, Labour and Welfare, the Minister of Economy, Trade and Industry, and the Minister of the Environment when he/she has conducted tests with regard to the substance subject to reporting under the items prescribed in Article 4, paragraph (7) or studies of hazardous properties prescribed in Article 5-4, paragraph (1), Article 24, paragraph (1) or Article 25-3, paragraph (1) (including cases in which information equivalent to that which would be obtained from said tests (limited to information that is not publicly known) has been obtained). When, as a result of said tests, the person obtains information specified by Ordinance of the Ministry of Health, Labour and Welfare, Ordinance of the Ministry of Economy, Trade and Industry, and Ordinance of the Ministry of the Environment indicating that the substance subject to reporting possesses the following properties, he/she shall report to that effect and give the details of such information, pursuant to the provisions of Ordinance of the Ministry of Health, Labour and Welfare, and Ordinance of the Ministry of Economy; provided, however that this shall not apply where said person has obtained said information as a result of a study of hazardous properties to which an instruction under the provisions of Article 5-4, paragraph (1), Article 24, paragraph (1) or Article 25-3, paragraph (1) pertains, and where said person is reporting the details of said information pursuant to these provisions: 例文帳に追加

第三十一条の二　監視化学物質、第二種特定化学物質、第四条第四項（第四条の二第九項において読み替えて準用する場合及び第五条の二第二項において準用する場合を含む。）の規定により公示された化学物質又は附則第二条第四項の規定により通商産業大臣が公示した同条第一項に規定する既存化学物質名簿に記載されている化学物質（以下「報告対象物質」という。）の製造又は輸入の事業を営む者は、その製造し、又は輸入した報告対象物質について、第四条第七項に規定する試験の項目又は第五条の四第一項、第二十四条第一項若しくは第二十五条の三第一項に規定する有害性の調査の項目に係る試験を行つた場合（当該試験を行つたと同等の知見（公然と知られていないものに限る。）が得られた場合を含む。）であつて、報告対象物質が次に掲げる性状を有することを示す知見として厚生労働省令、経済産業省令、環境省令で定めるものが得られたときは、厚生労働省令、経済産業省令、環境省令で定めるところにより、その旨及び当該知見の内容を厚生労働大臣、経済産業大臣及び環境大臣に報告しなければならない。ただし、第五条の四第一項、第二十四条第一項又は第二十五条の三第一項の規定による指示に係る有害性の調査により当該知見が得られた場合において、これらの規定によりその内容を報告するときは、この限りでない。 - 日本法令外国語訳データベースシステム

Article 31-2 (1) A person operating the business of manufacturing or importing any monitoring chemical substance, any Class II Specified Chemical Substance, any chemical substance that has been publicly notified pursuant to the provisions of paragraph (4) of Article 4 (including the cases in which it is applied mutatis mutandis pursuant to paragraph (9) of Article 4-2 and the cases in which it is applied mutatis mutandis pursuant to paragraph (2) of Article 5-2), any new chemical substance to which the confirmation under item (v) of paragraph (1) of Article 3 or paragraph (4) of Article 4-2 pertains, or any chemical substance listed in the List of Existing Chemical Substances prescribed in paragraph (1) of Article 2 of the Supplementary Provisions that has been publicly notified by the Minister of International Trade and Industry pursuant to the provisions of paragraph (4) of said Article (hereinafter referred to as a "substance subject to reporting") shall, when he/she has conducted tests pertaining to the items to be tested prescribed in paragraph (7) of Article 4 or pertaining to the studies of hazardous properties prescribed in paragraph (1) of Article 5-4, paragraph (1) of Article 24, or paragraph (1) of Article 25-3 (including the cases in which knowledge equivalent to that which would be obtained from said tests [limited to knowledge that is not publicly known] has been obtained) with regard to the substance subject to reporting he/she has manufactured or imported and if he/she has obtained, as a result thereof, knowledge specified by an Ordinance of the Ministry of Health, Labour and Welfare, Ordinance of the Ministry of Economy, Trade and Industry, and Ordinance of the Ministry of the Environment as one indicating that the substance subject to reporting possesses the following properties, report to the Minister of Health, Labour and Welfare, the Minister of Economy, Trade and Industry, and the Minister of the Environment to that effect and the details of said knowledge, pursuant to the provisions of an Ordinance of the Ministry of Health, Labour and Welfare, Ordinance of the Ministry of Economy, Trade and Industry, and Ordinance of the Ministry of the Environment; provided, however, that this shall not apply to the case where said person has obtained said knowledge as a result of a study of hazardous properties to which an instruction under the provisions of paragraph (1) of Article 5-4, paragraph (1) of Article 24, or paragraph (1) of Article 25-3 pertains and is reporting the details of said knowledge pursuant to these provisions: 例文帳に追加

第三十一条の二　監視化学物質、第二種特定化学物質、第四条第四項（第四条の二第九項において読み替えて準用する場合及び第五条の二第二項において準用する場合を含む。）の規定により公示された化学物質、第三条第一項第五号若しくは第四条の二第四項の確認に係る新規化学物質又は附則第二条第四項の規定により通商産業大臣が公示した同条第一項に規定する既存化学物質名簿に記載されている化学物質（以下「報告対象物質」という。）の製造又は輸入の事業を営む者は、その製造又は輸入した報告対象物質について、第四条第七項に規定する試験の項目又は第五条の四第一項、第二十四条第一項若しくは第二十五条の三第一項に規定する有害性の調査の項目に係る試験を行つた場合（当該試験を行つたと同等の知見（公然と知られていないものに限る。）が得られた場合を含む。）であつて、報告対象物質が次に掲げる性状を有することを示す知見として厚生労働省令、経済産業省令、環境省令で定めるものが得られたときは、厚生労働省令、経済産業省令、環境省令で定めるところにより、その旨及び当該知見の内容を厚生労働大臣、経済産業大臣及び環境大臣に報告しなければならない。ただし、第五条の四第一項、第二十四条第一項又は第二十五条の三第一項の規定による指示に係る有害性の調査により当該知見が得られた場合において、これらの規定によりその内容を報告するときは、この限りでない。 - 日本法令外国語訳データベースシステム